Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group.

R Berenson, J; Lichtenstein, A; Porter, L; A Dimopoulos, M; Bordoni, R; George, S; Lipton, A; Keller, A; Ballester, O; J Kovacs, M; A Blacklock, H; Bell, R; Simeone, J; J Reitsma, D; Heffernan, M; Seaman, J; D Knight, R

doi:10.1056/nejm199602223340802

Public

Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group.

Shared by NobleBlocks on Feb 22, 1996 • 12:00 AM UTC

Authors:

J R Berenson

A Lichtenstein

L Porter

Abstract

BACKGROUND: Skeletal complications are a major clinical manifestation of multiple myeloma. These complications are caused by soluble factors that stimulate osteoclasts to resorb bone. Bisphosphonates such as pamidronate inhibit osteoclastic activity and reduce bone resorption. METHODS: Patients with...

Discussions